October 2009
Pharmaceutical Representative;Oct2009, Vol. 39 Issue 10, p10
The article offers developments in the pharmaceutical industry in the U.S. Eli Lilly & Co. announces that it will not seek approval for arzoxifene, an osteoporosis treatment, because it failed during the Phase III clinical trials. Acadia Pharmaceuticals Inc. reports on the failure of pimavanserin, a treatment for patients with Parkinson's disease psychosis, during the Phase III trial. Bionovo Inc. presents the results of the Phase II clinical trial of Menerba, a drug for postmenopausal symptoms


Related Articles

  • American Academy of Neurology.  // BioWorld Today;4/15/2010, Vol. 21 Issue 72, p4 

    The article reports on the additional data provided by Acadia Pharmaceuticals Inc. from the first Phase III trial of pimavanserin in Parkinson's disease psychosis.

  • ACADIA completes enrollment in Phase III pimavanserin trial.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p9 

    The article reports on the enrollment completion by ACADIA Pharmaceuticals Inc. of its existing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP). The trial is a multi-center, double-blind, placebo-controlled study. It claims that the pimavanserin...

  • Acadia's Pimavanserin Fails in Phase III.  // Bioworld Week;9/7/2009, Vol. 17 Issue 36, p3 

    The article reports on the failure of Acadia Pharmaceuticals Inc.'s Phase III clinical trial on its pimavanserin in the U.S. It mentions that investors have retracted their investments after the failure of the said clinical trial. Meanwhile, pimavanserin was designed for psychosis and...

  • FSP Relationships: i3 Statprobe and Eli Lilly. Henderson, Lisa // Applied Clinical Trials;Mar2011 Partnerships Supplement, p15 

    The article focuses on the functional services provider (FSP) partnership between pharmaceutical services company i3 Statprobe and pharmaceutical company Eli Lilly & Co. in the U.S. It notes that the partnership of the two companies is a manifestation of how clinical research organizations...

  • Battle lines harden in osteoporosis market.  // Medical Marketing & Media;Jan1998, Vol. 33 Issue 1, p20 

    Reports on Eli Lilly & Co.'s release of its osteoporosis drug Evista (raloxifene) in the market. Promotion of the drug in medical journals; Comments of Wyeth Ayerst, which markets the osteoporosis drug Premarin, on the drug Evista.

  • FDA approves new labeling for Lilly's Evista.  // Drug Store News;1/11/99, Vol. 21 Issue 1, pCP6 

    Cites the United States Food and Drug Administration's (FDA) approval of new labeling for Evista (Raloxifene), an osteoporosis drug from Eli Lilly & Co. Evista's estimated sales in 1997; Inclusion of statistics from a recent study in the drug's labeling.

  • Lilly's Forteo May Transform Osteoporosis Treatment. Jarvis, Lisa // Chemical Market Reporter;5/21/2001, Vol. 259 Issue 21, p10 

    Reports on the expectations from Eli Lilly & Company's drug Forteo for osteoporosis. Market opportunity for an effective treatment for osteoporosis; Forteo's method of action; When osteoporosis develops.

  • Lilly gets O.K. for Evista.  // Indianapolis Business Journal;12/29/97, Vol. 18 Issue 42, p7 

    Reports on Indianapolis, Indiana-based Eli Lilly & Co.'s plans to introduce its osteoporosis drug called Evista. Approval from the US Food and Drug Administration to market the drug; Effectiveness of the drug without posing cancer risk associated with traditional hormone replacement therapy;...

  • Parkinson's Disease Update.  // PharmaWatch: CNS;August 2005, Vol. 4 Issue 8, p7 

    The article presents information about recent developments related to Parkinson' disease. Acadia Pharmaceuticals Inc. has received encouraging preliminary results from an ongoing clinical trial which show the company's serotonin acting drug, ACP-103, can help reduce symptoms of treatment-induced...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics